The demand for blood cancer treatments market (leukaemia, non-Hodgkin lymphoma, hodgkin lymphoma, multiple myeloma) worldwide is anticipated to reach US$ 5,489.3 million in 2022 and US$ 12,943.6 million (US$ 10.2% CAGR) in 2032. With the latest insights and statistics from the biggest pharmaceutical and healthcare device manufacturers across the globe, FMI presents an extensive analysis …